Your shopping cart


Total (VAT incl.)

VAT (21%)
You have not added any reports to the cart yet.
Request reports
If you prefer to place your order via e-mail
contact us at: digital@azierta.com

Events and news

Home > Blog > Azierta

Azierta, Azierta Foundation and Paredox Therapeutics partner to expand the clinical development of a novel oncology therapeutic in ovarian cancer

Cambridge, Massachusetts and Madrid, Spain – Paredox Therapeutics, LLC, Azierta Contract Scientific Support Consulting, S.L. and Azierta Foundation, announced today at the European Society for Medical Oncology (ESMO 2019) a partnership for co-development of Paredox’s novel therapeutic (PER-016) targeting mitochondria-based oxidative stress signaling pathways in ovarian cancer. 

 Azierta Contract Scientific Support Consulting, S.L. is a Science and Health consultancy firm committed to strengthening bonds between science and the business environment through the “Science to Business” concept. Azierta provides services in the field of medicinal products, Medical Devices, cosmetics, food supplements and biocides, offering complete solutions throughout products’ life cycle, from medical and regulatory support, to toxicology, manufacturing and distribution needs, market access and pharmacovigilance.  

 Mr. Ángel Navarro, Azierta’s CEO stated, “We are very excited to partner with Paredox in the development of this very exiting therapeutic. This is our first partnership and direct involvement in the development of an oncology asset through an innovative business model. We anticipate that Paredox’s groundbreaking science will change drug development business norms and will result in novel therapies for patients. 

 Paredox Therapeutics is a privately held pre-clinical biotechnology company based in Cambridge, Massachusetts. The company is currently developing a first-in-class oxidative stress modulator (PER-016) scheduled to enter Phase I clinical development in 1H20. This novel MOA targeted treatment approach is expected to have broad efficacy in various disease states of oxidative stress dysregulation. “This innovative partnership will allow us to expand into additional indications currently outside of our corporate strategy. This will ultimately speed up the process of reaching as many patients as possible sooner than anticipated with our exciting and potentially life-changing therapy, stated Jarrett Duncan, CEO of Paredox.  

 More information about Paredox Therapeutics and Azierta Foundation can be found onwww.ParedoxTherapeutics.com and www.Azierta.eu and www.fundacionazierta.com 


Media Contacts: 

 Paredox Therapeutics  

Jarrett Duncan 

George Naumov 

One Broadway, 14th floor 

Cambridge, MA 02142 


Email: j.duncan@paredoxtherapeutics.comg.naumov@paredoxtherapeutics.com  


Azierta Contract Scientific Support Consulting, S.L. and Azierta Foundation 

Ángel Navarro (Azierta’s CEO ) 

Eduardo Rodenas (VP Azierta Foundation) 

Via de las Dos Castillas 33 

Edificio 7 

28224 Pozuelo de Alarcon (Madrid) 

Tel. 91 277 1076 



Related posts


The science and health consulting firm has supported the Catalan pharmaceutical company in the areas of biosafety and biosecurity....

Read more

Landing in UK

Landing in UK

Read more

Leading innovation in pharma & health

100 professionals

Over 100 professionals

500 clients

Over 2,000 clients

9 year experience

10 years of experience


Leading innovation

Client oriented

100% client oriented


We help you in everything you need. Contact us by filling out the form or book an appointment for a video call with one of our experts.

We use "cookies" to improve your experience on our site. Cookies enable us to tailor messages and display ads to your interests. They also help us understand how our site is being used. By continuing to use our site you consent to use our cookies.

We are at your complete disposal for any inquiry

Thank you for getting in touch! We will contact you as soon as possible to help you out
There has been an error while submitting your form, please try again, or call us at 912 77 10 76